UBS Downgrades Auxilium Pharmaceuticals To Neutral

Analysts at UBS downgraded Auxilium Pharmaceuticals

from Buy to Neutral. Auxilium Pharmaceuticals shares have jumped 64.74% over the past 52 weeks, while the S&P 500 index has surged 17.63% in the same period. Auxilium Pharma's shares fell 3.98% to $29.88 in pre-market trading.